BIBW 2948
Alternative Names: BIBW-2948; BIBW2948 BSLatest Information Update: 21 Nov 2021
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Class Antiasthmatics; Antibronchitics
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bronchitis; Chronic obstructive pulmonary disease